Returning to Vancouver for the second year, "Particle Fever" has been a surprising hit amongst
documentary theatregoers worldwide. At a recent viewing, a panel of particle physicists were available for questions after the film.
The Canadian Radiation Protection Agency held their annual conference this year in Vancouver, bringing together the top safety professionals from across Canada to think about
issues from environmental safety to risk communication.
In a paper published today in the journal Nature Communications, the ALPHA collaboration reports on their
latest measurement of a fundamental property of antihydrogen, the ephemeral
antimatter twin to normal hydrogen.
The Honourable Michelle Rempel, Minister of State for Western
Economic Diversification, announced funding of $5.5 million to support TRIUMF in procuring a
new TR-24 cyclotron and developing the Institute for Accelerator-based Medical
Isotopes.
Chemistry plays a crucial role in many areas of TRIUMF's science
program. The nuclear medicine division at TRIUMF works closely with UBC's Medicinal Inorganic
Chemistry group and two TRIUMF collaborators from this group
have been recognized for their research excellence.
As part of a new initiative to stimulate interest in science, the Richmond Public Library has created a S&T lecture series with the inaugural talks presented by TRIUMF scientists.
The U.S. particle-physics community released a trend-setting report this week that outlines a compelling future vision. TRIUMF's Lia Merminga was one of the authors.
Astrophysicist Rocky Kolb’s lecture, "The Quantum and the Cosmos," traces the significance of the smallest particles to the biggest mysteries in the universe. TRIUMF and Science World hosted this lecture as part of the Unveiling the Universe series.
Led by TRIUMF and UBC, and with funding from NSERC, the
Isotopes for Science and Medicine program will enrich training experiences for young Canadian researchers in the production, preparation,
and innovative application of isotopes.
TRIUMF’s Nuclear Medicine group has been awarded an
NSERC Engage grant to support a new collaboration with B.C.-based biotechnology
start-up ImStar in the development of a promising new therapeutic drug for Lou Gehrig's disease.
